BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mótyán JA, Mahdi M, Hoffka G, Tőzsér J. Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease. Int J Mol Sci 2022;23:3507. [PMID: 35408866 DOI: 10.3390/ijms23073507] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Akinosoglou K, Schinas G, Gogos C. Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir. Viruses 2022;14:2540. [DOI: 10.3390/v14112540] [Reference Citation Analysis]
2 Brady DK, Gurijala AR, Huang L, Hussain AA, Lingan AL, Pembridge OG, Ratangee BA, Sealy TT, Vallone KT, Clements TP. A guide to COVID ‐19 antiviral therapeutics: a summary and perspective of the antiviral weapons against SARS‐CoV ‐2 infection. The FEBS Journal 2022. [DOI: 10.1111/febs.16662] [Reference Citation Analysis]
3 Sargsyan K, Mazmanian K, Lim C. A strategy for evaluating antiviral resistance: Application to small molecule drugs/inhibitors against SARS-CoV-2.. [DOI: 10.21203/rs.3.rs-1877306/v2] [Reference Citation Analysis]
4 Abdel-halim H, Hajar M, Hasouneh L, Abdelmalek SMA. Identification of Drug Combination Therapies for SARS-CoV-2: A Molecular Dynamics Simulations Approach. DDDT 2022;Volume 16:2995-3013. [DOI: 10.2147/dddt.s366423] [Reference Citation Analysis]
5 Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study. The Lancet Infectious Diseases 2022. [DOI: 10.1016/s1473-3099(22)00507-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
6 Issa SS, Sokornova SV, Zhidkin RR, Matveeva TV. The Main Protease of SARS-CoV-2 as a Target for Phytochemicals against Coronavirus. Plants 2022;11:1862. [DOI: 10.3390/plants11141862] [Reference Citation Analysis]
7 Costa AS, Martins JPA, de Melo EB. SMILES-based 2D-QSAR and similarity search for identification of potential new scaffolds for development of SARS-CoV-2 MPRO inhibitors. Struct Chem. [DOI: 10.1007/s11224-022-02008-9] [Reference Citation Analysis]
8 Wong CK, Au IC, Lau KT, Lau EH, Cowling BJ, Leung GM. Real-world effectiveness of early molnupiravir and nirmatrelvir/ritonavir among hospitalized, non-oxygen-dependent COVID-19 patients on admission during Hong Kong’s Omicron BA.2 wave: an observational study.. [DOI: 10.1101/2022.05.19.22275291] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]